Clinical Trial Update: Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib malate in patients with Von Hippel-Lindau disease and VHL-associated lesions; the study was terminated and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemangioblastoma
• Renal Cell Carcinoma
• Von Hippel-lindau Disease

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Von Hippel-Lindau Syndrome, Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2011-06-30